Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01720446
First received: October 29, 2012
Last updated: October 17, 2016
Last verified: October 2016
  Purpose
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.

Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: semaglutide
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Time from randomisation to first occurrence of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time from randomisation to first occurrence of an expanded composite cardiovascular outcome [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Time from randomisation to each individual component of the expanded composite cardiovascular outcome [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Time from randomisation to first occurrence of all-cause death, non-fatal MI, or non-fatal stroke [ Time Frame: Time from randomisation up to end of follow-up (up to max. 148 weeks) ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: glycosylated haemoglobin (HbA1c) [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: fasting plasma glucose [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: body weight [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: lipid profile [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: urinary albumin to creatinine ratio [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: vital signs [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]
  • Incidence during the treatment period in other treatment outcomes: hypoglycaemic events [ Time Frame: Week 0 - 143 ] [ Designated as safety issue: No ]
  • Incidence during the treatment period in other treatment outcomes: adverse events [ Time Frame: Weeks 0-143 ] [ Designated as safety issue: No ]
  • Occurrence during the treatment period in other treatment outcomes: anti-semaglutide antibodies [ Time Frame: Weeks 0-143 ] [ Designated as safety issue: No ]
  • Change from baseline to last assessment during the treatment period in other treatment outcomes: patient reported outcome (PRO) [ Time Frame: Week 0, up to week 143 ] [ Designated as safety issue: No ]

Enrollment: 3297
Study Start Date: February 2013
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Semaglutide 0.5 mg Drug: semaglutide
Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Experimental: Semaglutide 1.0 mg Drug: semaglutide
Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Placebo Comparator: Semaglutide placebo 0.5 mg Drug: placebo

Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.

Administered subcutaneously (s.c., under the skin).

Placebo Comparator: Semaglutide placebo 1.0 mg Drug: placebo

Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.

Administered subcutaneously (s.c., under the skin).


  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women with type 2 diabetes mellitus
  • Age above or equal to 50 years at screening and clinical evidence of cardiovascular disease or age above or equal to 60 years at screening and subclinical evidence of cardiovascular disease
  • Anti-diabetic drug naïve, or treated with one or two oral antidiabetic drug (OADs), or treated with human Neutral Protamin Hagedorn (NPH) insulin or long-acting insulin analogue or pre-mixed insulin, both types of insulin either alone or in combination with one or two OADs
  • HbA1c above or equal to 7.0% at screening

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Use of glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide, or other) or pramlintide within 90 days prior to screening
  • Use of any dipeptidyl peptidase 4 (DPP-IV) inhibitor within 30 days prior to screening
  • Treatment with insulin other than basal and pre-mixed insulin within 90 days prior to screening - except for short-term use in connection with intercurrent illness
  • Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg diabetes ketoacidosis) within 90 days prior to screening
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Acute coronary or cerebro-vascular event within 90 days prior to randomisation
  • Currently planned coronary, carotid or peripheral artery revascularisation
  • Chronic heart failure New York Heart Association (NYHA) class IV
  • Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma
  • Personal history of non-familial medullary thyroid carcinoma
  • Screening calcitonin above or equal to 50 ng/L
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01720446

  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35205-4731
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35216
United States, Arizona
Novo Nordisk Investigational Site
Chandler, Arizona, United States, 85224
United States, California
Novo Nordisk Investigational Site
Anaheim, California, United States, 92801
Novo Nordisk Investigational Site
Greenbrae, California, United States, 94904
Novo Nordisk Investigational Site
Lancaster, California, United States, 93534
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90017-4006
Novo Nordisk Investigational Site
Mission Hills, California, United States, 91345
Novo Nordisk Investigational Site
Monterey, California, United States, 93940
Novo Nordisk Investigational Site
Northridge, California, United States, 91325
Novo Nordisk Investigational Site
San Diego, California, United States, 92108
Novo Nordisk Investigational Site
San Ramon, California, United States, 94583
Novo Nordisk Investigational Site
Ventura, California, United States, 93003
United States, Colorado
Novo Nordisk Investigational Site
Aurora, Colorado, United States, 80045
United States, Connecticut
Novo Nordisk Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Novo Nordisk Investigational Site
Bradenton, Florida, United States, 34201
Novo Nordisk Investigational Site
Brooksville, Florida, United States, 34601
Novo Nordisk Investigational Site
Crystal River, Florida, United States, 34429
Novo Nordisk Investigational Site
Deland, Florida, United States, 32724
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32216
Novo Nordisk Investigational Site
Melbourne, Florida, United States, 32901
Novo Nordisk Investigational Site
Melbourne, Florida, United States, 32934
Novo Nordisk Investigational Site
Ocala, Florida, United States, 34471
Novo Nordisk Investigational Site
Ponte Vedra, Florida, United States, 32081
Novo Nordisk Investigational Site
St. Petersburg, Florida, United States, 33707
United States, Georgia
Novo Nordisk Investigational Site
Dunwoody, Georgia, United States, 30338
Novo Nordisk Investigational Site
Lawrenceville, Georgia, United States, 30046
United States, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois, United States, 60607
Novo Nordisk Investigational Site
Crystal Lake, Illinois, United States, 60012
Novo Nordisk Investigational Site
Gurnee, Illinois, United States, 60031
United States, Indiana
Novo Nordisk Investigational Site
Michigan City, Indiana, United States, 46360
Novo Nordisk Investigational Site
Mishawaka, Indiana, United States, 46545
United States, Kansas
Novo Nordisk Investigational Site
Wichita, Kansas, United States, 67205
United States, Kentucky
Novo Nordisk Investigational Site
Louisville, Kentucky, United States, 40206
Novo Nordisk Investigational Site
Louisville, Kentucky, United States, 40213
United States, Louisiana
Novo Nordisk Investigational Site
Monroe, Louisiana, United States, 71203
Novo Nordisk Investigational Site
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Novo Nordisk Investigational Site
Methuen, Massachusetts, United States, 01844
Novo Nordisk Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, Michigan
Novo Nordisk Investigational Site
Kalamazoo, Michigan, United States, 49048
United States, Missouri
Novo Nordisk Investigational Site
Chesterfield, Missouri, United States, 63017
Novo Nordisk Investigational Site
Kansas City, Missouri, United States, 64111
Novo Nordisk Investigational Site
St. Louis, Missouri, United States, 63128
Novo Nordisk Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nebraska
Novo Nordisk Investigational Site
Omaha, Nebraska, United States, 68114
Novo Nordisk Investigational Site
Omaha, Nebraska, United States, 68198-3020
United States, New Hampshire
Novo Nordisk Investigational Site
Lebanon, New Hampshire, United States, 03756
Novo Nordisk Investigational Site
Nashua, New Hampshire, United States, 03063
United States, New Jersey
Novo Nordisk Investigational Site
Mine Hill, New Jersey, United States, 07803
Novo Nordisk Investigational Site
Toms River, New Jersey, United States, 08755-8050
United States, New York
Novo Nordisk Investigational Site
Albany, New York, United States, 12206
Novo Nordisk Investigational Site
New York, New York, United States, 10001
Novo Nordisk Investigational Site
Rochester, New York, United States, 14609
Novo Nordisk Investigational Site
Staten Island, New York, United States, 10301
Novo Nordisk Investigational Site
West Seneca, New York, United States, 14224
United States, North Carolina
Novo Nordisk Investigational Site
Asheboro, North Carolina, United States, 27203
Novo Nordisk Investigational Site
Asheville, North Carolina, United States, 28801
Novo Nordisk Investigational Site
Chapel Hill, North Carolina, United States, 27517
Novo Nordisk Investigational Site
Greenville, North Carolina, United States, 27834
Novo Nordisk Investigational Site
Raleigh, North Carolina, United States, 27612
Novo Nordisk Investigational Site
Whiteville, North Carolina, United States, 28472
Novo Nordisk Investigational Site
Wilmington, North Carolina, United States, 28401
United States, Ohio
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45219
Novo Nordisk Investigational Site
Cleveland, Ohio, United States, 44106
Novo Nordisk Investigational Site
Franklin, Ohio, United States, 45005
Novo Nordisk Investigational Site
Mason, Ohio, United States, 45040-6815
Novo Nordisk Investigational Site
Maumee, Ohio, United States, 43537
United States, Oklahoma
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Novo Nordisk Investigational Site
Beaver, Pennsylvania, United States, 15009-1957
Novo Nordisk Investigational Site
McMurray, Pennsylvania, United States, 15317
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States, 19152
United States, South Carolina
Novo Nordisk Investigational Site
Greer, South Carolina, United States, 29651
Novo Nordisk Investigational Site
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Novo Nordisk Investigational Site
Bartlett, Tennessee, United States, 38133
Novo Nordisk Investigational Site
Kingsport, Tennessee, United States, 37660
Novo Nordisk Investigational Site
Memphis, Tennessee, United States, 38163
Novo Nordisk Investigational Site
Nashville, Tennessee, United States, 37212
United States, Texas
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75218
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75230
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75231
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75390-9302
Novo Nordisk Investigational Site
Fort Worth, Texas, United States, 76132
Novo Nordisk Investigational Site
Houston, Texas, United States, 77074
Novo Nordisk Investigational Site
Irving, Texas, United States, 75061-2210
Novo Nordisk Investigational Site
Longview, Texas, United States, 75605
Novo Nordisk Investigational Site
Odessa, Texas, United States, 79761
Novo Nordisk Investigational Site
Plano, Texas, United States, 75075
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78224
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78228-3419
Novo Nordisk Investigational Site
Sugar Land, Texas, United States, 77478
United States, Utah
Novo Nordisk Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Vermont
Novo Nordisk Investigational Site
South Burlington, Vermont, United States, 05403-7205
United States, Virginia
Novo Nordisk Investigational Site
Richmond, Virginia, United States, 23219
Novo Nordisk Investigational Site
Winchester, Virginia, United States, 22601-3834
Novo Nordisk Investigational Site
Winchester, Virginia, United States, 22601
United States, Washington
Novo Nordisk Investigational Site
Wenatchee, Washington, United States, 98801-2028
United States, Wisconsin
Novo Nordisk Investigational Site
Madison, Wisconsin, United States, 53792
Algeria
Novo Nordisk Investigational Site
Annaba, Algeria, 23000
Novo Nordisk Investigational Site
Oran, Algeria, 31000
Novo Nordisk Investigational Site
Setif, Algeria, 19000
Novo Nordisk Investigational Site
Tizi Ouzou, Algeria, 15000
Argentina
Novo Nordisk Investigational Site
Caba, Argentina, C1093AAS
Novo Nordisk Investigational Site
Caba, Argentina, C1180AAX
Novo Nordisk Investigational Site
Caba, Argentina, C1440AAD
Novo Nordisk Investigational Site
Caba, Argentina
Novo Nordisk Investigational Site
Cordoba, Argentina, 5000
Novo Nordisk Investigational Site
Mar del Plata, Argentina, B7600FZN
Novo Nordisk Investigational Site
Morón, Argentina, B1708IFF
Australia, New South Wales
Novo Nordisk Investigational Site
Blacktown, New South Wales, Australia, 2148
Novo Nordisk Investigational Site
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Novo Nordisk Investigational Site
Ipswich, Queensland, Australia, 4305
Australia, South Australia
Novo Nordisk Investigational Site
Daw Park, South Australia, Australia, 5041
Novo Nordisk Investigational Site
Keswick, South Australia, Australia, 5035
Australia, Victoria
Novo Nordisk Investigational Site
Box Hill, Victoria, Australia, 3128
Novo Nordisk Investigational Site
Fitzroy, Victoria, Australia, 3065
Australia, Western Australia
Novo Nordisk Investigational Site
Fremantle, Western Australia, Australia, 6160
Brazil
Novo Nordisk Investigational Site
Curitiba, Parana, Brazil, 80030-110
Novo Nordisk Investigational Site
Belém, Para, Brazil, 66073-000
Novo Nordisk Investigational Site
Campinas, Sao Paulo, Brazil, 13059-740
Novo Nordisk Investigational Site
São Paulo, Sao Paulo, Brazil, 01228-000
Novo Nordisk Investigational Site
São Paulo, Sao Paulo, Brazil, 01244-030
Novo Nordisk Investigational Site
São Paulo, Sao Paulo, Brazil, 04038-002
Novo Nordisk Investigational Site
São Paulo, Sao Paulo, Brazil, 05403-900
Novo Nordisk Investigational Site
Porto Alegre, Brazil, 90035-170
Bulgaria
Novo Nordisk Investigational Site
Pleven, Bulgaria, 5800
Novo Nordisk Investigational Site
Sofia, Bulgaria, 1324
Novo Nordisk Investigational Site
Sofia, Bulgaria, 1606
Novo Nordisk Investigational Site
Varna, Bulgaria, 9010
Canada, Alberta
Novo Nordisk Investigational Site
Calgary, Alberta, Canada, T2V 4J2
Novo Nordisk Investigational Site
Edmonton, Alberta, Canada, T6G 2E1
Canada, Manitoba
Novo Nordisk Investigational Site
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, Newfoundland and Labrador
Novo Nordisk Investigational Site
St. John's, Newfoundland and Labrador, Canada, A1E 2C2
Canada, Ontario
Novo Nordisk Investigational Site
Cambridge, Ontario, Canada, N1R 7L6
Novo Nordisk Investigational Site
Cornwall, Ontario, Canada, K6H 4M4
Novo Nordisk Investigational Site
London, Ontario, Canada, N6A 4V2
Novo Nordisk Investigational Site
Smiths Falls, Ontario, Canada, K7A 4W8
Novo Nordisk Investigational Site
Toronto, Ontario, Canada, M5C 2T2
Novo Nordisk Investigational Site
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Novo Nordisk Investigational Site
Drummondville, Quebec, Canada, J2B 7T1
Novo Nordisk Investigational Site
Victoriaville, Quebec, Canada, G6P 6P6
Novo Nordisk Investigational Site
Westmount, Quebec, Canada, H3Z 1E5
Canada
Novo Nordisk Investigational Site
Quebec, Canada, G1V 4G5
Denmark
Novo Nordisk Investigational Site
Aarhus C, Denmark, 8000
Novo Nordisk Investigational Site
Gentofte, Denmark, 2820
Novo Nordisk Investigational Site
Hellerup, Denmark, 2900
Novo Nordisk Investigational Site
Hvidovre, Denmark, 2650
Novo Nordisk Investigational Site
Odense, Denmark, 5000
Germany
Novo Nordisk Investigational Site
Elsterwerda, Germany, 04910
Novo Nordisk Investigational Site
Essen, Germany, 45219
Novo Nordisk Investigational Site
Falkensee, Germany, 14612
Novo Nordisk Investigational Site
Freiburg, Germany, 79106
Novo Nordisk Investigational Site
Hamburg, Germany, 22607
Novo Nordisk Investigational Site
Münster, Germany, 48145
Novo Nordisk Investigational Site
Oldenburg, Germany, 23758
Novo Nordisk Investigational Site
St. Ingbert, Germany, 66386
India
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India, 500003
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India, 500034
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India, 500082
Novo Nordisk Investigational Site
Visakhapatnam, Andhra Pradesh, India, 530002
Novo Nordisk Investigational Site
Bangalore, Karnataka, India, 560034
Novo Nordisk Investigational Site
Mysore, Karnataka, India, 570001
Novo Nordisk Investigational Site
Kochi, Kerala, India, 682041
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400008
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400010
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400012
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400016
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400022
Novo Nordisk Investigational Site
Delhi, New Delhi, India, 110002
Novo Nordisk Investigational Site
New Dehli, New Delhi, India, 110029
Novo Nordisk Investigational Site
Chandigarh, Punjab, India, 160012
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India, 600086
Novo Nordisk Investigational Site
Vellore, Tamil Nadu, India, 632004
Novo Nordisk Investigational Site
Kolkata, West Bengal, India, 700032
Novo Nordisk Investigational Site
Kolkata, West Bengal, India, 700054
Novo Nordisk Investigational Site
New Delhi, India, 110095
Novo Nordisk Investigational Site
Pune, India, 411011
Israel
Novo Nordisk Investigational Site
Holon, Israel, 58100
Novo Nordisk Investigational Site
Jerusalem, Israel, 91120
Novo Nordisk Investigational Site
Nahariya, Israel, 22100
Novo Nordisk Investigational Site
Petah-Tikva, Israel, 49100
Novo Nordisk Investigational Site
Tel Hashomer, Israel, 52621
Novo Nordisk Investigational Site
Tel-Aviv, Israel, 64239
Italy
Novo Nordisk Investigational Site
Bergamo, Italy, 24127
Novo Nordisk Investigational Site
Chieti Scalo, Italy, 66100
Novo Nordisk Investigational Site
Olbia, Italy, 07026
Novo Nordisk Investigational Site
Padova, Italy, 35128
Novo Nordisk Investigational Site
Primo Piano Palazzina Ambulato, Italy, 40133
Novo Nordisk Investigational Site
Siena, Italy, 53100
Malaysia
Novo Nordisk Investigational Site
Kota Samarahan, Malaysia, 94300
Novo Nordisk Investigational Site
Kuala Lumpur, Malaysia, 59100
Novo Nordisk Investigational Site
Kuching, Malaysia, 93586
Novo Nordisk Investigational Site
Melaka, Malaysia, 75400
Novo Nordisk Investigational Site
Serdang, Malaysia, 43000
Novo Nordisk Investigational Site
Seremban, Malaysia, 70300
Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico, 44130
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico, 44600
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico, 44670
Novo Nordisk Investigational Site
Cuernavaca, Morelos, Mexico, 62250
Novo Nordisk Investigational Site
Mexico City, México, D.F., Mexico, 03300
Novo Nordisk Investigational Site
Mexico City, México, D.F., Mexico, 14000
Novo Nordisk Investigational Site
México D.F., México, D.F., Mexico, 11550
Novo Nordisk Investigational Site
Tampico, Tamaulipas, Mexico, 89000
Novo Nordisk Investigational Site
Aguascalientes, Mexico, 20230
Novo Nordisk Investigational Site
San Luis Potosi, Mexico, 78200
Poland
Novo Nordisk Investigational Site
Bialystok, Poland, 15-445
Novo Nordisk Investigational Site
Gdansk, Poland, 80-858
Novo Nordisk Investigational Site
Lublin, Poland, 20-044
Novo Nordisk Investigational Site
Warszawa, Poland, 01-192
Novo Nordisk Investigational Site
Zabrze, Poland, 41-800
Russian Federation
Novo Nordisk Investigational Site
Arkhangelsk, Russian Federation, 163001
Novo Nordisk Investigational Site
Arkhangelsk, Russian Federation, 163045
Novo Nordisk Investigational Site
Barnaul, Russian Federation, 656045
Novo Nordisk Investigational Site
Kazan, Russian Federation, 420043
Novo Nordisk Investigational Site
Moscow, Russian Federation, 117997
Novo Nordisk Investigational Site
Moscow, Russian Federation, 119435
Novo Nordisk Investigational Site
Novosibirsk, Russian Federation, 630047
Novo Nordisk Investigational Site
Penza, Russian Federation, 440026
Novo Nordisk Investigational Site
Saint-Petersburg, Russian Federation, 199034
Novo Nordisk Investigational Site
Saratov, Russian Federation, 410012
Novo Nordisk Investigational Site
Saratov, Russian Federation, 410053
Novo Nordisk Investigational Site
Smolensk, Russian Federation, 214019
Novo Nordisk Investigational Site
Yaroslavl, Russian Federation, 150062
Spain
Novo Nordisk Investigational Site
Almería, Spain, 04001
Novo Nordisk Investigational Site
Antequera, Spain, 29200
Novo Nordisk Investigational Site
Pozuelo de Alarcon, Spain, 28223
Novo Nordisk Investigational Site
Sanlúcar de Barrameda - Cádiz-, Spain, 15540
Novo Nordisk Investigational Site
Sevilla, Spain, 41010
Novo Nordisk Investigational Site
Vic (Barcelona), Spain, 08500
Taiwan
Novo Nordisk Investigational Site
Chiayi City, Taiwan, 600
Novo Nordisk Investigational Site
Tainan city, Taiwan, 710
Novo Nordisk Investigational Site
Taipei, Taiwan, 114
Novo Nordisk Investigational Site
Taoyuan, Taiwan, 333
Thailand
Novo Nordisk Investigational Site
Bangkok, Thailand, 10330
Novo Nordisk Investigational Site
Bangkok, Thailand, 10400
Novo Nordisk Investigational Site
Bangkok, Thailand, 10700
Turkey
Novo Nordisk Investigational Site
Ankara, Turkey, 06100
Novo Nordisk Investigational Site
Ankara, Turkey, 06110
Novo Nordisk Investigational Site
Antalya, Turkey, 07058
Novo Nordisk Investigational Site
Canakkale, Turkey, 17020
Novo Nordisk Investigational Site
Denizli, Turkey, 20070
Novo Nordisk Investigational Site
Istanbul, Turkey, 34096
Novo Nordisk Investigational Site
Istanbul, Turkey, 34722
Novo Nordisk Investigational Site
Istanbul, Turkey, 34890
Novo Nordisk Investigational Site
Izmir, Turkey, 35340
Novo Nordisk Investigational Site
Kocaeli, Turkey, 41380
United Kingdom
Novo Nordisk Investigational Site
Aberdeen, United Kingdom, AB25 2ZD
Novo Nordisk Investigational Site
Birmingham, United Kingdom, B9 5SS
Novo Nordisk Investigational Site
Leeds, United Kingdom, LS25 1AN
Novo Nordisk Investigational Site
Liverpool, United Kingdom, L9 7AL
Novo Nordisk Investigational Site
Northwood, United Kingdom, HA6 2RN
Novo Nordisk Investigational Site
Sidcup, United Kingdom, DA14 6LT
Novo Nordisk Investigational Site
Swansea, United Kingdom, SA6 6NL
Novo Nordisk Investigational Site
Torquay, United Kingdom, TQ2 7AA
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Publications:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01720446     History of Changes
Other Study ID Numbers: NN9535-3744  2012-002839-28  U1111-1131-7227 
Study First Received: October 29, 2012
Last Updated: October 17, 2016
Health Authority: Algeria: Ministry of Health
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia
Australia: Department of Health and Ageing Therapeutic Goods Administration
Brazil: National Health Surveillance Agency
Bulgaria: Ministry of Health
Canada: Public Health Agency of Canada
Denmark: Danish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: The Italian Medicines Agency
Malaysia: Ministry of Health
Mexico: National Institute of Public Health, Health Secretariat
Poland: Ministry of Health and Social Security
Spain: Spanish Agency of Medicines and Health Care Products
Taiwan: Department of Health
Thailand: Ministry of Public Health
Turkey: Ministry of Health Drug and Pharmaceutical Department
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Russia: Ministry of Health of the Russian Federation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on December 09, 2016